HBOT Conversations:
Dr. Paul Harch & Autism
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on Autism is the seventh in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
In episode 7 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch about Autism.
The percentage of children with Autism is increasing at an alarming rate. In order to successfully treat Autism and navigate around the roadblocks, Dr. Harch explains that it’s important to understand that Autism is not a psychiatric diagnosis. Autism is a wounding condition of the brain, without all of the potential contributors being identified to the wounding process.
Dr. Harch was the first to treat a series of children with Autism using Hyperbaric Oxygen Therapy; a therapy which in and of itself is neuroplastic (it is a neuroplast — affecting neuroplasticity). He states that there’s a plethora of information on the fact that Autism is a physical brain abnormality, and that’s what’s causing this Autism phenomenon. Functional imaging scans that have been done on these Autistic children shows 90% of them have a problem involving primarily the temporal lobes and frontal lobes; mostly temporal lobes. Dr. Harch has treated a good series of these children with Hyperbaric Oxygen Therapy and about 80% of them will respond to the treatment. There are various causes, which may explain why 100% don’t respond to HBOT, since there are different insults to the brains and/or it’s environmental. But, Dr. Harch stresses that there’s no such thing as a genetic epidemic, so this Autism epidemic we’re seeing must either be caused by environmental factors or infectious agents.
Dr. Harch affirms that the underlying nature of Autism is that there’s a dominant immune dysfunction in these children that often manifests in the GI tract, but also in the brain. Dr. Harch recommends our viewers read this beautiful article by Dr. Dan Rossignol, a Family Practice Physician with two autistic sons. In the article Dr. Rossignol reviews all of the pathophysiology — the disease processes — that have been identified in Autistic children, and he reviews all of the science of Hyperbaric Oxygen Therapy and the effect it has on all of those disease processes. In the end, HBOT is shown to be a good match for the treatment of Autism.
di Girolamo asks Dr. Harch if Autism appears to be an inflammatory issue, with Dr. Harch agreeing that it does seem to appear that way. Dr. Harch went on to explain that of the 8,1001 genes that have been shown to be affected in human cells by a single Hyperbaric Oxygen exposure, the largest clusters involved are the anti-inflammatory genes — upregulation is turned on and there’s suppression of the pro-inflammatory genes. Plus, there are many genes that are activated within the immune system which also supports the use of HBOT for the treatment of Autism as a dominant immune dysfunction.
The studies have been controversial and complicated on Hyperbaric Oxygen Therapy for Autism. But contrary to the results of these studies, Dr. Harch is here to say that the proof is in the imaging. He has imaging revealing that after only one treatment — sometimes it’s a series of treatments — changes are seen in these children’s brains, and there’s improvement in profusion (such as in the temporal lobes).
Dr. Harch professes that what he’s been trying to do all these years, these decades, is to answer a simple question, “Does Hyperbaric Oxygen Therapy work for your condition or not?” He explains it’s critical to start with HBOT solely and not throw a bunch of other therapies into the mix because then you have too many variables, and you won’t know exactly what’s helping and what’s not. He explains Hyperbaric Oxygen Therapy is a foundation biological therapy, and declares there is no identified therapy out there that can do what Hyperbaric Oxygen can do; including activating 40% of our genome. There’s nothing.
Dr. Harch references Chapter 12 of his book, The Oxygen Revolution, and says “I’m sorry but if your doctor is giving you negative information, flatly ignore him! Go get this therapy for your child!” Treating with HBOT is no different than if you dosed the child with a drug, or a drug combination. This is a two component drug we’re dosing with that’s safe and effective — pressure and oxygen. We encourage you to try it, because it could change your life if you or your child are a part of this 80% success rate.
Subscribe Now, It’s Free!
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Healing of spongiosus-cutaneous fistula with Hyperbaric Oxygen Therapy (HBOT): a case report.
Abstract: We present a case of a spongiosus-cutaneous fistula in a 39-year-old man with recurrent episodes of cutaneous abscess in dorsal middle third penis (5 - 3 cm) treated with Hyperbaric Oxygen Therapy (HBOT). After emptying nodular abscess, the patient was...
Clinical Trial – Caudal Block,Saddle Block, Anorectal Surgery
Anorectal surgery includes pilonidal sinus, hemorrhoidectomy, anal fissure, and anal fistula
operations. Various surgical and anesthetic techniques have been used to increase the level
of analgesia in perioperative period and decrease the length of stay in the hospital. In this
study, investigators investigate the effects of routinely applied anesthesia techniques
during anorectal surgery, caudal block and saddle block, on patients’ perioperative
hemodynamic values, sensory and motor block levels, and postoperative pain scores.
Clinical Trial – Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with recurrent
mucosal inflammation. Clinically, the disease is characterized by bloody diarrhea, abdominal
pain, and constitutional symptoms such as fever and weight loss. Treatment strategies vary
based on disease activity and target various aspects of the inflammatory cascade. Options
include: anti-inflammatory drugs (mesalamine), immunosuppressive or modulatory medications
(corticosteroids, thiopurines, cyclosporine) and biologic agents (Anti-TNF). Disease severity
can be wide ranging, and nearly 25% of UC patients are hospitalized for acute severe disease.
Of these patients, 30% will undergo colectomy after the acute episode, a quarter of which
will experience post-operative complications. Although there has been great progress in
treatment of UC over the past decade, even with the anti-TNF agent infliximab, the one-year
remission rate for patients not responding to conservative management is barely 20%.
Furthermore, corticosteroids have significant long-term consequences and immune suppressive
drugs such as 6-mercaptopurine, azathioprine and infliximab have been associated with serious
adverse events including life-threatening infections and lymphomas. With growing evidence
that the pathogenesis of UC is multi-factorial and involves a complex interaction of genetic
and environmental factors, newer treatment modalities are being evaluated to target the
mucosal immune response and mucosal inflammatory regulatory system.
Hyperbaric oxygen offers a promising new treatment option since it targets both tissue
hypoxia and inflammation. Recent small scales studies evaluating the impact of hyperbaric
oxygen treatment in acute ulcerative colitis flares demonstrated improved outcomes. The
mechanisms underlying the improvement are not known. In this study, we will treat ulcerative
colitis flares with hyperbaric oxygen and measure changes in both markers of tissue hypoxia
and inflammation. We hypothesize that hyperbaric oxygen will (a) improve outcomes, and (b)
show reductions in markers of both tissue hypoxia and inflammation.